TY - JOUR
T1 - High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia
AU - van den Ancker, Willemijn
AU - van Luijn, Marvin M.
AU - Chamuleau, Martine E. D.
AU - Kelder, Angèle
AU - Feller, Nicole
AU - Terwijn, Monique
AU - Zevenbergen, Adri
AU - Schuurhuis, Gerrit-Jan
AU - Ham, S. Marieke van
AU - Westers, Theresia M.
AU - Ossenkoppele, Gert J.
AU - van de Loosdrecht, Arjan A.
PY - 2014
Y1 - 2014
N2 - The presence of class II-associated invariant chain (CLIP) on leukemic cells is negatively associated with clinical outcome in untreated acute myeloid leukemia (AML). CLIP plays a role in the immune escape of leukemic cells, suggesting that it impairs the immunogenicity of minimal residual disease (MRD) cells causing a relapse. Here, we demonstrate that CLIP expression on leukemia-associated phenotype (LAP)-positive cells during follow-up is significantly correlated with a shortened relapse-free survival, even in those patients who are generally considered as MRD(low) (0.01-0.1% LAP(+) cells). Consequently, CLIP evaluation could be of additional value in the evaluation of MRD to predict a relapse of AML
AB - The presence of class II-associated invariant chain (CLIP) on leukemic cells is negatively associated with clinical outcome in untreated acute myeloid leukemia (AML). CLIP plays a role in the immune escape of leukemic cells, suggesting that it impairs the immunogenicity of minimal residual disease (MRD) cells causing a relapse. Here, we demonstrate that CLIP expression on leukemia-associated phenotype (LAP)-positive cells during follow-up is significantly correlated with a shortened relapse-free survival, even in those patients who are generally considered as MRD(low) (0.01-0.1% LAP(+) cells). Consequently, CLIP evaluation could be of additional value in the evaluation of MRD to predict a relapse of AML
U2 - https://doi.org/10.1016/j.leukres.2014.03.014
DO - https://doi.org/10.1016/j.leukres.2014.03.014
M3 - Article
C2 - 24731748
SN - 0145-2126
VL - 38
SP - 691
EP - 693
JO - Leukemia research
JF - Leukemia research
IS - 6
ER -